The FDA creates an advisory list for dietary supplements; researchers in Israel bio-printed a small-scale heart with human tissue and blood vessels; patient advocates lobby to lift a ban on a controversial fertility treatment.
The FDA is launching a Dietary Supplement Ingredient Advisory List to alert the public when ingredients that appear to be unlawfully marketed are contained in dietary supplements. The FDA said inclusion on the list may not necessarily indicate safety concerns; it may be for reasons including situations in which the ingredient does not fit the definition of a dietary ingredient or the ingredient requires a premarket notification that was not submitted.Researchers in Israel created a small scale, 3-D printed heart with human tissue and blood vessels in an effort to pave the way for the future possibility of producing human organs for transplant, according to Medical Xpress. The printed hearts would need to be trained to behave like real ones. They currently have the ability to contract but lack the ability to pump. Researchers hope to test them in about a year by transplanting them into animals.A group of patient advocates, bioethicists, and scientists are lobbying to have a ban lifted on mitochondrial replacement therapy, a controversial fertility treatment that combines genetic material from an intended father and mother as well as a female donor, reported STAT News. While a Greek woman gave birth to a healthy baby with 3 biological parents last week, the United States banned the procedure in a 2015 congressional amendment. The ban has been renewed annually but supporters say that the procedure could help women who are carriers of genetic diseases have healthy, biologically related children.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More